Clinical Trial

Glucagon-like-peptide-1 Receptor Agonists in Patients Receiving Maintenance Dialysis

Study acronym: GUARD-1
Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
This study aims to determine if GLP1RA is safe and tolerable in maintenance dialysis population, adherence, and feasibility of a larger definitive cardiovascular outcome trial in this population. Participants will be randomized 1:1 to either weekly subcutaneous semaglutide versus usual care and followed for 26 weeks.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-06-03.
Status change: Not Yet Recruiting → Recruiting 2026-06-22
Trial Details
NCT Number NCT07017270
Lead Sponsor Unity Health Toronto
Conditions Kidney Disease, Chronic, Diabetes, Dialysis, End Stage Kidney Disease (ESRD)
Enrollment 100 participants
Start Date 2025-11-27
Primary Completion 2027-07 (estimated)
Study Completion 2027-09 (estimated)
Updated on ClinicalTrials.gov 2026-06-26